Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ProMetic Life Sciences -- Ignore unavailable to you. Want to Upgrade?

To: axial who wrote (201)	4/24/2025 7:04:42 AM
From: Mohit Badhani	Respond to of 250

Thanks for sharing this comprehensive overview—it's clear that Galapagos, FibroGen, and ProMetic are making notable progress in the race to develop next-generation IPF therapies. What stands out is that while Esbriet and Ofev currently dominate treatment, they mainly slow disease progression without reversing fibrosis or offering a survival benefit. The promising results from early-phase trials by these three companies highlight a critical shift toward more effective interventions. If their upcoming Phase 3 trials replicate the efficacy seen in Phase 2, we could see a real turning point in how IPF is managed clinically. Given the rising prevalence and the significant unmet need, the Idiopathic Pulmonary Fibrosis Treatment Market is poised for strong growth, projected to hit $5 billion by 2025 according to a report by Expert Market Research. This not only represents a major opportunity for biopharma companies but also renewed hope for patients living with this life-threatening condition. Keeping an eye on the Phase 3 outcomes and potential FDA approvals from these developers will be crucial for anyone tracking this space, whether from an investment or patient care perspective.